U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H30N4O5S
Molecular Weight 450.552
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ACOTIAMIDE

SMILES

COC1=CC(O)=C(C=C1OC)C(=O)NC2=NC(=CS2)C(=O)NCCN(C(C)C)C(C)C

InChI

InChIKey=TWHZNAUBXFZMCA-UHFFFAOYSA-N
InChI=1S/C21H30N4O5S/c1-12(2)25(13(3)4)8-7-22-20(28)15-11-31-21(23-15)24-19(27)14-9-17(29-5)18(30-6)10-16(14)26/h9-13,26H,7-8H2,1-6H3,(H,22,28)(H,23,24,27)

HIDE SMILES / InChI

Molecular Formula C21H30N4O5S
Molecular Weight 450.552
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21123674 | https://www.ncbi.nlm.nih.gov/pubmed/10871292 | https://www.astellas.com/en/corporate/news/pdf/130605_1_Eg.pdf

Acotiamide (Acofide(®)), an oral first-in-class prokinetic drug, is under global development by Zeria Pharmaceutical Co. Ltd and Astellas Pharma Inc. for the treatment of patients with functional dyspepsia. The drug modulates upper gastrointestinal motility to alleviate abdominal symptoms resulting from hypomotility and delayed gastric emptying. It exerts its activity in the stomach via muscarinic receptor inhibition, resulting in enhanced acetylcholine release and inhibition of acetylcholinesterase activity. Acofide® is launched in Japan for treating functional dyspepsia.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ACOFIDE

Approved Use

Acofide (Acotiamide hydrochloride hydrate) improves gastrointestinal motility and promotes excretion of stomach contents by inhibiting acetylcholinesterase activities. It is usually used for the treatment of postprandial fullness, upper abdominal bloating, and early satiation due to functional dyspepsia.

Launch Date

2013
PubMed

PubMed

TitleDatePubMed
Drug-drug interactions of Z-338, a novel gastroprokinetic agent, with terfenadine, comparison with cisapride, and involvement of UGT1A9 and 1A8 in the human metabolism of Z-338.
2004 Aug 23
Prokinetics and fundic relaxants in upper functional GI disorders.
2008 Dec
[Functional and motor gastrointestinal disorders].
2008 Oct
Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats.
2008 Sep
A dose-ranging, placebo-controlled, pilot trial of Acotiamide in patients with functional dyspepsia.
2009 Mar
Acotiamide (Z-338) as a possible candidate for the treatment of functional dyspepsia.
2010 Jun
Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosage.
2010 Jun
Patents

Patents

Sample Use Guides

In general, for adults, take 1 tablet (100mg of the active ingredient) at a time, 3 times a day before meals.
Route of Administration: Oral
Acotiamide (0.3 and 1 uM) significantly enhanced the contraction of guinea pig gastric body strips induced by electrical field stimulation
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:26:26 GMT 2023
Edited
by admin
on Fri Dec 15 16:26:26 GMT 2023
Record UNII
D42OWK5383
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ACOTIAMIDE
INN   WHO-DD  
INN  
Official Name English
acotiamide [INN]
Common Name English
ACOTIAMIDE [MI]
Common Name English
4-THIAZOLECARBOXAMIDE, N-(2-(BIS(1-METHYLETHYL)AMINO)ETHYL)-2-((2-HYDROXY-4,5-DIMETHOXYBENZOYL)AMINO)-
Systematic Name English
Acotiamide [WHO-DD]
Common Name English
N-(2-(BIS(1-METHYLETHYL)AMINO)ETHYL)-2-((2-HYDROXY-4,5-DIMETHOXYBENZOYL)AMINO)THIAZOLE-4-CARBOXAMIDE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C267
Created by admin on Fri Dec 15 16:26:26 GMT 2023 , Edited by admin on Fri Dec 15 16:26:26 GMT 2023
NCI_THESAURUS C47792
Created by admin on Fri Dec 15 16:26:26 GMT 2023 , Edited by admin on Fri Dec 15 16:26:26 GMT 2023
Code System Code Type Description
INN
8506
Created by admin on Fri Dec 15 16:26:26 GMT 2023 , Edited by admin on Fri Dec 15 16:26:26 GMT 2023
PRIMARY
NCI_THESAURUS
C65214
Created by admin on Fri Dec 15 16:26:26 GMT 2023 , Edited by admin on Fri Dec 15 16:26:26 GMT 2023
PRIMARY
ChEMBL
CHEMBL2107723
Created by admin on Fri Dec 15 16:26:26 GMT 2023 , Edited by admin on Fri Dec 15 16:26:26 GMT 2023
PRIMARY
MERCK INDEX
m1383
Created by admin on Fri Dec 15 16:26:26 GMT 2023 , Edited by admin on Fri Dec 15 16:26:26 GMT 2023
PRIMARY
CAS
185106-16-5
Created by admin on Fri Dec 15 16:26:26 GMT 2023 , Edited by admin on Fri Dec 15 16:26:26 GMT 2023
PRIMARY
FDA UNII
D42OWK5383
Created by admin on Fri Dec 15 16:26:26 GMT 2023 , Edited by admin on Fri Dec 15 16:26:26 GMT 2023
PRIMARY
PUBCHEM
5282338
Created by admin on Fri Dec 15 16:26:26 GMT 2023 , Edited by admin on Fri Dec 15 16:26:26 GMT 2023
PRIMARY
EPA CompTox
DTXSID40870163
Created by admin on Fri Dec 15 16:26:26 GMT 2023 , Edited by admin on Fri Dec 15 16:26:26 GMT 2023
PRIMARY
DRUG BANK
DB12482
Created by admin on Fri Dec 15 16:26:26 GMT 2023 , Edited by admin on Fri Dec 15 16:26:26 GMT 2023
PRIMARY
WIKIPEDIA
ACOTIAMIDE
Created by admin on Fri Dec 15 16:26:26 GMT 2023 , Edited by admin on Fri Dec 15 16:26:26 GMT 2023
PRIMARY
SMS_ID
300000036947
Created by admin on Fri Dec 15 16:26:26 GMT 2023 , Edited by admin on Fri Dec 15 16:26:26 GMT 2023
PRIMARY
DRUG CENTRAL
4908
Created by admin on Fri Dec 15 16:26:26 GMT 2023 , Edited by admin on Fri Dec 15 16:26:26 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY